cordlife one chance, one choice.

CORDLIFE GROUP LIMITED

Full Year Unaudited Financial Statement for the Year Ended 30 June 2015

PART 1 – INFORMATION REQUIRED FOR QUARTERLY (Q1, Q2, Q3), HALF YEAR AND FULL YEAR ANNOUNCEMENTS

1(a)(i) An income statement and statement of comprehensive income (for the group) together with a comparative statement for the corresponding period of the immediately preceding financial year

	Group 12 months ended 30 June		+/(-) Increase/ (Decrease)
	2015	**2014**	
	$'000	$'000	%
Revenue	57,583	49,087	17.3
Cost of sales	(17,560)	(14,229)	23.4
Gross profit	40,023	34,858	14.8
Other operating income	773	1,273	(39.3)
Selling and marketing expenses	(17,657)	(12,155)	45.3
Administrative expenses	(17,254)	(14,966)	15.3
Finance income	409	288	42.0
Finance costs	(185)	(217)	(14.7)
Profit before income tax from operations*	6,109	9,081	(32.7)
Share of results of associate	(436)	(2,350)	(81.4)
Impairment loss on investment in associate	(2,646)	-	n.m
Fair value gain on investment properties	265	110	>100.0
Fair value changes on financial asset designated at fair value through profit or loss	10,364	18,716	(44.6)
Fair value changes on derivative	12,922	-	n.m
Gain on transfer from associate to financial asset designated at fair value through profit or loss	-	6,297	n.m
Exchange differences	4,653	-	n.m
Finance income	6,634	-	n.m
Finance costs	(4,597)	-	n.m
Profit before income tax	33,268	31,854	4.4
Income tax expense	(1,143)	(1,474)	(22.5)
Profit for the year	32,125	30,380	5.7

1(a)(i) An income statement and statement of comprehensive income (for the group) together with a comparative statement for the corresponding period of the immediately preceding financial year (cont'd)

	Group 12 months ended 30 June 2015	2014	+/(-) Increase/ (Decrease)
	$'000	$'000	%
Other comprehensive income for the year, net of tax:			
Items that may be reclassified subsequently to profit and loss			
Reclassification adjustment on transfer of investment in associate to financial asset designated at fair value through profit or loss	-	(341)	n.m
Share of foreign currency translation of associate	(310)	88	n.m
Foreign currency translation	(80)	(419)	(80.9)
Total comprehensive income for the year	31,735	29,708	6.8
Profit/(loss) for the year attributable to:			
- Shareholders of the company	32,460	30,521	6.4
- Non-controlling interest	(335)	(141)	>100.0
	32,125	30,380	5.7
Total comprehensive income/(expense) for the year attributable to:			
- Shareholders of the company	32,013	29,845	7.3
- Non-controlling interest	(278)	(137)	>100.0
	31,735	29,708	6.8

n.m denotes not meaningful

*In order to provide more clarity to readers, the Group has presented separately its share of results of associate, impairment loss on investment in associate, fair value changes and exchange differences, finance income and finance costs that relate to the convertible bond, loan to third party and fixed rate note from its profit before income tax from operations.

1(a)(ii) Notes to the income statement

	Group 12 months ended 30 June		
	2015	**2014**	
	$'000	$'000	
Depreciation of property, plant and equipment	1,461	1,290	[1]
Amortisation of software	227	218	
Reversal of doubtful debts	(8)	-	
Allowance for doubtful debts and bad debts written off	519	192	
Foreign exchange loss/(gain)	257	(2)	
Under/(over)provision of tax in prior years	39	(128)	
Other miscellaneous income	773	1,273	[2]

Notes

1. The increase in depreciation is due to additional laboratory equipment purchased for Cordlife Sciences India to accommodate the increased sales volume.

2. The decrease in other miscellaneous income is mainly due to the Group recognising an upfront fee of S$680,000 for providing training and know-how services to StemLife Berhad ("StemLife") under the licensing agreement signed in April 2014. There was no similar upfront fee income in FY2015.

1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year

	Group As at		Company As at	
	30 June 2015	**30 June 2014**	**30 June 2015**	**30 June 2014**
	$'000	$'000	$'000	$'000
ASSETS				
Non-current assets				
Investment in associate	13,543	16,819	13,543	18,220
Investment in subsidiaries	-	-	21,034	21,034
Financial asset designated at fair value through profit or loss*	60,858	50,494	60,858	50,494
Derivative asset*	37,971	-	37,971	-
Property, plant and equipment	9,567	8,409	7,098	6,545
Investment properties	3,795	4,830	3,795	4,830
Intangible asset	2,543	1,941	1,164	424
Trade receivables	54,606	45,961	43,458	39,258
Other receivables*	98,513	229	98,513	18
	281,396	128,683	287,434	140,823
Current assets				
Cash and cash equivalents	14,699	32,643	11,668	28,451
Short-term investments	1,234	988	-	-
Fixed deposits	13,295	11,778	11,949	11,500
Pledged fixed deposits	320	348	-	-
Trade receivables	15,256	12,890	7,278	6,858
Other receivables*	4,210	1,054	2,724	397
Prepayments	1,702	1,678	961	733
Inventories	851	645	347	233
Amounts owing by subsidiaries	-	-	11,368	6,156
	51,567	62,024	46,295	54,328

* Please refer to page 21 to 23 for the proposed disposal of equity interest and convertible note in China Cord Blood Corporation, and loan provided to Magnum Opus International Holdings Limited.

1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year (cont'd)

	Group As at		Company As at	
	30 June 2015 $'000	**30 June 2014** $'000	**30 June 2015** $'000	**30 June 2014** $'000
Current liabilities				
Trade and other payables	11,597	8,887	7,027	4,615
Deferred revenue	3,989	5,378	1,994	3,123
Amounts owing to subsidiaries	-	-	25,090	1,917
Income tax payable	1,103	1,558	463	1,296
Interest-bearing borrowings	4,486	4,448	4,486	4,448
	21,175	20,271	39,060	15,399
Net current assets	30,392	41,753	7,235	38,929
Non-current liabilities				
Other payables	1,306	81	1,306	-
Deferred revenue	23,627	20,473	13,111	12,160
Deferred tax liabilities	91	188	105	226
Interest-bearing borrowings	7,355	8,402	7,355	8,402
Notes payable	117,463	-	117,463	-
Amounts owing to subsidiary	-	-	-	21,035
	149,842	29,144	139,340	41,823
Net assets	161,946	141,292	155,329	137,929
Capital and reserves				
Share capital	96,657	96,657	96,657	96,657
Treasury shares	(9,901)	(3,898)	(9,901)	(3,898)
Accumulated profits	78,633	51,359	67,998	44,703
Other reserves	(2,983)	(2,644)	575	467
Non-controlling interests	(460)	(182)	-	-
Total equity	161,946	141,292	155,329	137,929

1(b)(ii) **Aggregate amount of Group's borrowings and debt securities**

	As at	
	30 June 2015 $'000	**30 June 2014** $'000
Amount repayable in one year or less, or on demand		
- Loan I – secured	306	268
- Loan II – secured	3,500	3,500
- Loan III – secured	680	680
Amount repayable after one year		
- Loan I – secured	5,315	5,682
- Loan II – secured	-	-
- Loan III – secured	2,040	2,720
- Notes payable	117,463	-
	129,304	12,850

Loan I, Loan II and Loan III are secured by:

a) First legal mortgage of the leasehold properties and investment properties (the "Properties") of Cordlife Group Limited (the "Company");

b) The assignment of the rights, title and interest with respect to the Properties; and

c) Charge over all current receivables of the Company.

Loan I is drawn-down in different tranches and repayable in 240 monthly instalments. It will be repaid in full in June 2031.

Loan II is a revolving loan facility and is repayable on demand.

Loan III is a 5 year term loan with yearly principal repayments. It will be repaid in full in November 2018.

On 29 October 2014, the Group issued S$120 million in aggregate principal amount of 4.9% fixed rate notes due 2017 (the "Notes") under its S$500 million Multicurrency Debt Issuance Programme.

The Notes constitute direct, unconditional, unsubordinated and unsecured obligations of the Company and rank *pari passu*, without any preference or priority among themselves, and *pari passu* with all other present and future unsecured obligations (other than subordinated obligations and priorities created by law) of the Company from time to time outstanding. The Notes are redeemable only upon maturity on 28 October 2017.

1(c) A statement of cash flows (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year

	Group 12 months ended 30 June	
	2015	**2014**
	$'000	$'000
Operating activities		
Profit before income tax	33,268	31,854
Adjustments for:		
Depreciation	1,461	1,290
Amortisation	227	218
Allowance for doubtful debts	511	192
Gain on disposal of property, plant and equipment	(53)	(12)
Interest income	(7,043)	(288)
Interest expense	4,782	217
Share-based compensation expense	108	45
Share of results of associate	436	2,350
Impairment loss on investment in associate	2,646	-
Unrealised share of other (income)/expense from associate	(106)	318
Fair value gain on investment properties	(265)	(110)
Fair value changes on financial asset designated as fair value through profit or loss	(10,364)	(18,716)
Gain on transfer of investment in associate to financial asset designated as fair value through profit or loss	-	(6,297)
Fair value gain on derivative	(12,922)	-
Unrealised exchange gain	(4,780)	(281)
Operating cash flows before movements in working capital	7,906	10,780
Increase in trade receivables	(11,522)	(8,179)
(Increase)/decrease in other receivables, deposits and prepayments	(1,147)	14
Increase in inventories	(206)	(210)
Increase in trade payables and other payables	1,201	1,315
Increase in deferred revenue	1,765	1,339
Cash (used in)/generated from operations	(2,003)	5,059
Interest received	2,564	115
Interest paid	(3,126)	(217)
Income tax paid	(1,664)	(1,290)
Net cash (used in)/generated from operating activities	(4,229)	3,667

1(c) A statement of cash flows (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year (cont'd)

	Group 12 months ended 30 June	
	2015	**2014**
	$'000	$'000
Investing activities		
Purchase of property, plant and equipment	(1,882)	(1,544)
Purchase of intangible assets	(908)	(305)
Proceeds from disposal of property, plant and equipment	754	–
Placement of short term investment	(246)	(646)
Acquisition of associate	–	(8,124)
Dividends from associate	–	917
Acquisition of convertible bond, net of transaction cost	(57,303)	–
Transfer (to)/from term deposits, net	(1,047)	3,222
Acquisition of subsidiaries	–	(3,158)
Net cash used in investing activities	(60,632)	(9,638)
Financing activities		
Transfer from/(to) pledged fixed deposits	28	(14)
Proceeds from interest-bearing borrowings	–	6,900
Repayment of interest-bearing borrowings	(1,009)	(247)
Loan to external party, net of transaction cost	(57,683)	–
Dividends paid	(5,186)	(5,338)
Proceeds from issue of notes, net of transaction cost	116,797	–
Purchase of treasury shares	(6,003)	(3,795)
Proceeds from issue of shares	–	33,548
Share issue expense	–	(439)
Net cash generated from financing activities	46,944	30,615
Net (decrease)/increase in cash and cash equivalents	(17,917)	24,644
Cash and cash equivalents at the beginning of the financial year	32,643	7,986
Effects of exchange rate changes on the balance of cash	(27)	13
Cash and cash equivalents at end of the financial year	14,699	32,643

1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year

Group	Share capital $'000	Treasury shares $'000	Accumulated profits $'000	Share-based compensation reserve $'000	Capital reserve $'000	Merger reserve $'000	Acquisition reserve $'000	Foreign currency translation reserve $'000	Non-controlling interest $'000	Total $'000
Balance at 1 July 2013	53,548	(103)	26,176	–	568	534	(2,184)	(931)	(45)	77,563
Profit for the year	–	–	30,521	–	–	–	–	–	(141)	30,380
Other comprehensive (expense)/income										
- Net effect of foreign currency translation	–	–	–	–	–	–	–	(423)	4	(419)
- Share of other comprehensive income of associate	–	–	–	–	–	–	–	88	–	88
- Transfer of investment in associate to financial asset designated at fair value through profit or loss	–	–	–	–	–	–	–	(341)	–	(341)
Total comprehensive income/ (expense) for the year, net of tax	–	–	30,521	–	–	–	–	(676)	(137)	29,708
<u>Contributions by and distributions to owners</u>										
Issuance of shares as consideration for acquisition of associate	10,000	–	–	–	–	–	–	–	–	10,000
Issuance of shares pursuant to private placement	33,548	–	–	–	–	–	–	–	–	33,548
Placement expenses taken to equity	(439)	–	–	–	–	–	–	–	–	(439)
Dividends	–	–	(5,338)	–	–	–	–	–	–	(5,338)
Issuance of performance share grants	–	–	–	45	–	–	–	–	–	45
Purchase of treasury shares	–	(3,795)	–	–	–	–	–	–	–	(3,795)
Total contributions by and distributions to owners	43,109	(3,795)	(5,338)	45	–	–	–	–	–	34,021
Balance at 30 June 2014	96,657	(3,898)	51,359	45	568	534	(2,184)	(1,607)	(182)	141,292

1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year (cont'd)

Company	Share capital $'000	Treasury shares $'000	Accumulated profits $'000	Share-based compensation reserve $'000	Capital reserve $'000	Total $'000
Balance at 1 July 2013	53,548	(103)	16,818	–	422	70,685
Profit for the year	–	–	33,223	–	–	33,223
Other comprehensive income	–	–	–	–	–	–
Total comprehensive income for the financial year, net of tax	–	–	33,223	–	–	33,223
Contributions by and distributions to owners						
Issuance of shares as consideration for acquisition	10,000	–	–	–	–	10,000
Issuance of shares pursuant to private placement	33,548	–	–	–	–	33,548
Placement expenses taken to equity	(439)	–	–	–	–	(439)
Dividends	–	–	(5,338)	–	–	(5,338)
Purchase of treasury shares	–	(3,795)	–	–	–	(3,795)
Issuance of performance share grants	–	–	–	45	–	45
Total contributions by and distributions to owners	43,109	(3,795)	(5,338)	45	–	34,021
Balance at 30 June 2014	96,657	(3,898)	44,703	45	422	137,929

1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year (cont'd)

Group	Share capital $'000	Treasury shares $'000	Accumulated profits $'000	Share-based compensation reserve $'000	Capital reserve $'000	Merger reserve $'000	Acquisition reserve $'000	Foreign currency translation reserve $'000	Non-controlling interest $'000	Total $'000
Balance at 1 July 2014	96,657	(3,898)	51,359	45	568	534	(2,184)	(1,607)	(182)	141,292
Profit for the year	–	–	32,460	–	–	–	–	–	(335)	32,125
Other comprehensive (expense)/income										
- Net effect of foreign currency translation	–	–	–	–	–	–	–	(137)	57	(80)
- Share of other comprehensive expense of associate	–	–	–	–	–	–	–	(310)	–	(310)
Total comprehensive income/ (expense) for the year, net of tax	–	–	32,460	–	–	–	–	(447)	(278)	31,735
<u>Contributions by and distributions to owners</u>										
Purchase of treasury shares	–	(6,003)	–	–	–	–	–	–	–	(6,003)
Grant of share awards to employees	–	–	–	108	–	–	–	–	–	108
Dividends	–	–	(5,186)	–	–	–	–	–	–	(5,186)
Total contributions by and distributions to owners	–	(6,003)	(5,186)	108	–	–	–	–	–	(11,081)
Balance at 30 June 2015	96,657	(9,901)	78,633	153	568	534	(2,184)	(2,054)	(460)	161,946

1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year (cont'd)

Company	**Share capital** $'000	**Treasury shares** $'000	**Accumulated profits** $'000	**Share-based compensation reserve** $'000	**Capital reserve** $'000	**Total** $'000
Balance at 1 July 2014	96,657	(3,898)	44,703	45	422	137,929
Profit for the year, representing total comprehensive income for the year	–	–	28,481	–	–	28,481
Contributions by and distributions to owners						
Purchase of treasury shares	–	(6,003)	–	–	–	(6,003)
Grant of share awards to employees	–	–	–	108	–	108
Dividends	–	–	(5,186)	–	–	(5,186)
Total contributions by and distributions to owners	–	(6,003)	(5,186)	108	–	(11,081)
Balance at 30 June 2015	96,657	(9,901)	67,998	153	422	155,329

1(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State also the number of shares that may be issued on conversion of all the outstanding convertibles, as well as the number of shares held as treasury shares, if any, against the total number of issued shares excluding treasury shares of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

Group and Company	Number of shares	Share capital (S$)
As at 30 June 2014	264,103,354	96,656,721
Purchase of treasury shares[1]	(4,806,000)	–
As at 30 June 2015	**259,297,354**	**96,656,721**

[1] As at 30 June 2015, the Company held 8,228,000 (30 June 2014: 3,422,000) treasury shares against 259,297,354 (30 June 2014: 264,103,354) issued ordinary shares excluding treasury shares.

1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year

	As at	
	30 June 2015 No. of shares	**30 June 2014 No. of shares**
Total number of issued shares	267,525,354	267,525,354
Less: Treasury shares	(8,228,000)	(3,422,000)
Total number of issued shares excluding treasury shares	259,297,354	264,103,354

1(d)(iv) A statement showing all sales, transfers, disposal, cancellation and/or use of treasury shares as at the end of the current financial period reported on

There were no sales, transfers, disposal, cancellation and/or use of treasury shares during the current period reported on.

2. Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice

The figures have not been audited or reviewed by the Company's auditors.

3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of matter)

Not applicable.

4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied

Except as disclosed in note (5) below, the financial results for the current year reported on have been presented using the same accounting policies and methods of computation as presented in the Group's most recently audited annual financial statements.

5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change

The Group has adopted all new and revised Financial Reporting Standard ("FRS") and Interpretations of FRS ("INT FRS") which became effective for the Group's financial year beginning 1 July 2014.

The adoption of these new/revised FRS and INT FRS did not result in any substantial change to the Group's accounting policies and has no material/significant impact on the financial statements of the Group for the current reporting period or the prior year's reporting period.

6. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends

	Group 12 months ended 30 June	
Basic Earnings Per Share	**2015**	**2014**
Earnings per ordinary share of the group for the financial year based on net profit attributable to shareholders of the Company:		
Profit attributable to shareholders of the Company (S$ '000)	32,460	30,521
Weighted average number of shares in issue during the period ('000)	260,043	256,520
Basic earnings per share ("EPS") based on weighted average number of ordinary shares (cents)	12.48	11.90
Diluted Earnings Per Share		
Earnings per ordinary share of the group for the financial year based on net profit attributable to shareholders of the Company:		
Profit attributable to shareholders of the Company (S$ '000)	32,460	30,521
Weighted average number of shares in issue during the period ('000)	260,343	256,585
Diluted earnings per share ("EPS") based on weighted average number of ordinary shares (cents)	12.47	11.90

Notes:

Basic earnings per share are calculated by dividing profit net of tax, attributable to shareholders of the Company by the weighted average number of ordinary shares outstanding during the financial period.

Diluted earnings per share are calculated by dividing profit net of tax, attributable to shareholders of the Company by the weighted average number of ordinary shares outstanding during the financial period plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares.

Potential ordinary shares shall be treated as dilutive only when their conversion to ordinary shares would decrease earnings per share or increase loss per share.

7. Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the (a) current financial period reported on and (b) immediately preceding financial year

	Group		Company	
	30 June 2015 (cents)	**30 June 2014 (cents)**	**30 June 2015 (cents)**	**30 June 2014 (cents)**
Net asset value per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the financial year reported on	62.46	53.50	59.90	52.23

The number of shares in issue used in calculating the net asset value per share as at 30 June 2015 and 30 June 2014 is 259,297,354 and 264,103,354 respectively.

8. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. The review must discuss any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors. It must also discuss any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on

COMPARING 12 MONTHS 2015 ("FY2015") AGAINST 12 MONTHS 2014 ("FY2014")

Income Statement

Revenue

Revenue increased by 17.3% or S$8.5 million from S$49.1 million in FY2014 to S$57.6 million in FY2015. The increase in revenue was due mainly to an increase in the number of client deliveries, from approximately 15,880 in FY2014 to approximately 21,085 in FY2015. The increase in client deliveries was due to increased awareness as a result of increased marketing and client acquisition efforts. In particular, there was an increase in marketing expenditure in the Group's Indian subsidiary to increase brand awareness amongst prospective clients and establish its presence in more cities.

Cost of sales

Cost of sales increased by 23.4% or S$3.3 million in FY2015 compared to FY2014. The increase in cost of sales was in line with the increase in client deliveries from FY2014 to FY2015.

Gross profit and gross profit margin

Gross profit increased by 14.8% or S$5.2 million due to the increase in new client deliveries.

Gross profit margin decreased from 71.0% in FY2014 to 69.5% in FY2015, due mainly to an increase in revenue contribution from operations with lower margins.

Other operating income

Other operating income decreased by 39.3% or approximately S$500,000 in FY2015 compared to FY2014. Grant income from SPRING Singapore decreased from S$253,000 in FY2014 to S$37,000 in FY2015. In FY2014, the Group recognised an upfront fee of S$680,000 for providing training and know-how services to StemLife under a the licensing agreement signed in April 2014. There were no similar upfront fees and grant income in FY2015.

The decrease was offset by an increase in rental income derived from its investment properties by S$61,000 in FY2015 compared to FY2014. In FY2015, there was also a gain on disposal of investment property of S$54,000 and royalties from licensing of cord lining technology to StemLife and China Cord Blood Corporation ("CCBC") of approximately S$219,000 in FY2015. There were no such gain on disposals and royalties in FY2014.

Selling and marketing expenses

Selling and marketing expenses increased by 45.3% or S$5.5 million in FY2015 compared to FY2014. This was mainly attributable to the Group's Indian subsidiary where selling and marketing expenses increased by S$4.3 million. Television commercial were aired in India for the first time in FY2015 as part of a through-the-line integrated marketing plan, which alone accounted for approximately S$1.9 million during the year. There was also an increase in newspaper advertising, digital marketing and client activation activities. These additional promotional activities had been strategically planned to increase existing market share in India.

The increase was also attributable to the increase in staff related costs of S$1.6 million. The Group's entities in Singapore, India and Philippines have increased their headcounts to cater to the increasing business volume.

Administrative expenses

Administrative expenses increased by 15.3% or S$2.3 million in FY2015 compared to FY2014 due mainly to increase in staff cost from annual salary increments and an increase in the number of full time employees. The increase was also partly attributable to increase in legal and professional fees of approximately S$137,000 mainly arising from the establishment of the S$500 million Multicurrency Debt Issuance Programme and legal fees incurred in relation to an investigation by the Competition Commission of Singapore into an alleged infringement by the Company of the Competition Act (Cap. 50B), as announced on 14 October 2014.

Profit before income tax from operations

As a result of the foregoing, our profit before income tax from operations for FY2015 is lower than FY2014 at S$6.1 million.

Share of results of associate

Our share of loss in associate was approximately S$436,000 for FY2015 as compared to S$2.4 million for FY2014.

In FY2014, the Group completed its acquisition of 31.81% of the issued shares in StemLife. For FY2015, the Group accounted for its share of loss in StemLife amounting to approximately S$295,000 and amortisation of intangibles arising from the acquisition of S$141,000.

For FY2014, share of loss in CCBC and StemLife are approximately S$2.2 million and S$128,000 respectively. The loss in CCBC is mainly attributable to cash and non-cash expenses incurred as a result of the convertible note issued by CCBC as well as the non-cash fair value losses derived from such financial instruments. On 27 September 2013, Mr Yee Pinh Jeremy stepped down from the board of directors of CCBC. The Group was of the view that it had lost significant influence over CCBC and no longer regarded its investment in CCBC as an associate. The Group ceased to equity account for CCBC's results with effect from 27 September 2013 and the investment in associate was transferred to financial asset designated at fair value through profit or loss. A gain on the transfer of approximately S$6.3 million was recognised in FY2014.

Impairment loss on investment in associate

In FY2015, the Group recognised an impairment loss on investment in StemLife amounting to S$2.6 million. No similar impairment loss is being recognised in FY2014.

Fair value gain on investment properties

Certain units owned by the Group in A'Posh Bizhub have been designated as investment properties because these units are allocated to be leased to third parties to earn rental income or for capital appreciation. Investment properties are initially recognised at cost and subsequently measured at fair value which reflects the market conditions at the end of the reporting period. The Group engaged an independent professional valuer to value these investment properties, resulting in a fair value gain in FY2015 which is recorded in the income statement.

Fair value changes on financial asset designated at fair value through profit or loss

The Group recorded fair value gain on its investment in CCBC designated at fair value through profit or loss of S$10.4 million for FY2015 (FY2014: gain of S$18.7 million). The fair value changes are computed based on the changes in CCBC's last traded price as at 30 June 2014 of US$5.52 (approximately S$6.90 at US$1: S$1.2507) and 30 June 2015 of US$6.16 (approximately S$8.32 at US$1: S$ 1.3508) for FY2015 (FY2014: last traded price as at 30 June 2013 of US$2.81 (approximately S$3.56 at US$1: S$1.2668) and 30 June 2014 of US$5.52 (approximately S$6.90 at US$1: S$1.2507)). The fair value changes are recognised directly in the profit or loss.

Fair value changes on derivative

On 10 November 2014, the Company and Magnum Opus International Holding Limited ("Magnum") completed the acquisition of a 7% senior convertible note (the "Convertible Bond") due 3 October 2017 issued by CCBC to Golden Meditech Holdings Limited in the principal amount of US$50 million (the "CGL Acquisition"). The Company and Magnum also entered into a facility agreement pursuant to which the Company will lend Magnum funds in an aggregate amount of US$46,500,000 (the "Magnum Loan").

As the Convertible Bond provides the Company the option to convert the bond into shares in CCBC, the Company is required to separately compute the fair value changes on the conversion option component and recognise these changes in profit or loss. Fair value changes on the conversion option is mainly affected by the time to maturity of the bond, the share price of CCBC as at the reporting date compared to the date of acquisition and the value of the bond as a function of the cash inflow from the bond at the redemption date.

The Group recorded fair value gain on derivative for FY2015 of approximately S$12.9 million (FY2014: S$Nil).

Exchange differences

Due to strengthening of the US$ against the S$, unrealised foreign exchange gain of approximately S$4.7 million was recognised on the Magnum Loan and the Convertible Bond for FY2015 (FY2014: S$Nil).

Finance income

Finance income of approximately S$6.6 million was recognised for FY2015 (FY2014: S$Nil) on the Magnum Loan and the Convertible Bond.

Finance costs

Finance costs of approximately S$4.6 million was recognised on the Notes for FY2015 (FY2014: S$Nil).

Tax

For FY2015, the share of results of associate was reported net of tax. Fair value changes, impairment loss on investment in associate and exchange differences were not taxable. For FY2014, share of results of associate was reported net of tax and fair value changes were not taxable. Adjusting for these non-taxable items, the effective tax rate for FY2015 was 18.7%, compared to an effective tax rate for FY2014 of 16.2%. The increase in effective tax rate in 2015 was mainly due to the deferred tax asset not recognised on tax losses.

Balance sheet

Cash and cash equivalents, fixed deposits and short-term investments

As at 30 June 2015, the Group maintained a strong balance sheet, with cash and cash equivalents, fixed deposits and short-term investments of S$29.2 million (30 June 2014: S$45.4 million). The decrease in cash and cash equivalents in FY2015 was mainly due to purchase of treasury shares and dividends paid amounting to approximately S$6.0 million and S$5.2 million respectively. It was also due to net cash used in operating activities of approximately S$4.2 million which comprised mainly operating cash flows before movements in working capital of S$7.9 million, net working capital outflow of S$9.9 million, net interest payment of S$0.6 million, and tax payment of S$1.7 million.

Net working capital outflow of approximately S$9.9 million in FY2015 was due to the following:

- increase in trade receivables of approximately S$11.5 million;
- increase in other receivables, deposits and prepayments of approximately S$1.1 million;
- increase in inventory of approximately S$0.2 million;
- increase in trade and other payables of approximately S$1.2 million and
- increase in deferred revenue of approximately S$1.8 million.

The net cash used in operating activities was offset by proceeds from issue of the Notes, net of transaction costs, of S$116.8 million. This was in turn offset by the Magnum Loan, net of transaction costs, of S$57.7 million and the acquisition of the Convertible Bond, net of transaction costs, of S$57.3 million.

Investment in associate

The investment in associate as at 30 June 2015 represents the Group's 31.81% interest in StemLife.

Financial asset designated at fair value through profit or loss

The Group's interest in CCBC is recognised as a financial asset designated at fair value through profit or loss. It is valued based on CCBC's last traded share price as at 30 June 2015 of US$6.16 (approximately S$8.32 at US$1: S$1.3508) (as at 30 June 2014: US$5.52 (approximately S$6.90 at US$1: S$1.2507)).

Trade receivables, non-current

Non-current trade receivables represents cord blood and umbilical cord lining banking service revenues receivable under instalment payment plans that have yet to be billed to the customers. Upon billing, the billed amount will be receivable under the same terms as the current trade receivables.

Other receivables, non-current

Non-current other receivables increased by S$98.3 million to S$98.5 million as at 30 June 2015 (30 June 2014: S$229,000). On 10 November 2014, the Group entered into the Magnum Loan and CGL Acquisition.

The Magnum Loan is classified as loans and receivables and accounted for based on amortised cost. The carrying amount of the Magnum Loan as at 30 June 2015 was S$62.0 million (30 June 2014: S$Nil) and was classified under other receivables on the balance sheet.

On acquisition of the Convertible Bond, the Group was required to bifurcate the financial instrument into bond and conversion option components, which are recognised as loans and receivables carried at amortised cost and a derivative respectively. The bond component is classified as non-current other receivables on the balance sheet at a carrying value on 30 June 2015 of approximately S$36.5million (30 June 2014: S$Nil).

Derivative asset

The conversion option component is classified as a derivative and is carried at a fair value of S$38.0 million as at 30 June 2015 (30 June 2014: S$Nil). The fair value of the conversion option is affected by the time to maturity of the bond, the share price of CCBC as at the reporting date compared to the date of acquisition and the value of the bond as a function of the cash inflow from the bond at the redemption date.

Notes payable

The Notes are carried at amortised cost using the effective interest rate and are classified as “Notes Payable” on the balance sheet at S$117.5 million (30 June 2014: S$Nil).

The Proposed Disposal to Golden Meditech Holdings Limited of: (A) 7,314,015 Ordinary Shares in China Cord Blood Corporation; and (B) a 7% Senior Unsecured Convertible Note Due 2017 issued by China Cord Blood Corporation to the Company

An Extraordinary General Meeting will be held on Monday, 14 September 2015 at 3 p.m. for the purpose of considering the proposed disposal of the terms and subject to the conditions set out in the purchase agreement (the “Agreement”) dated 8 May 2015 with Golden Meditech Holdings Limited (the “Purchaser”), pursuant to which the Company has agreed to sell and the Purchaser has agreed to purchase from the Company 7,314,015 ordinary shares of par value US$0.0001 per share (the “Sale Shares”) in CCBC and a 7% senior unsecured Convertible Note due 3 October 2017 issued by CCBC to the Company in the principal amount of US$25,000,000 (the "Proposed Disposal"), the principal terms of which are set out in the Circular to Shareholders dated 26 August 2015 (the “Circular”).

Under the terms of the Agreement,

(a) the total consideration for the sale of the Sale Shares (the "Share Consideration") is the aggregate of (i) US$46,809,696, being the product of the US$6.40 Base Acquisition Price and the total number of Sale Shares (being 7,314,015) and (ii) if CCBC declares any distribution between the date of the Agreement and the completion date of the Proposed Disposal (the "Completion Date"), the amount of distribution per CCBC Share multiplied by 7,314,015, to the extent that such distribution is not paid to the Company prior to the Completion Date; and

(b) the total consideration for the sale of the Convertible Note (the "Note Consideration") shall be the aggregate of (i) US$5,100,000, (ii) US$56,377,728, being the product of the US$6.40 Base Acquisition Price and the total number of Conversion Shares into which the Convertible Note is then convertible (being 8,809,020) and (iii) the total amount of interest accrued but unpaid on the Convertible Note during the period from 3 October 2014 to the Completion Date[1] and (iv) if CCBC declares any distribution between the date of the Agreement and the Completion Date, the amount of distribution per CCBC Share multiplied by 8,809,020, to the extent that such distribution is not paid to the Company prior to the Completion Date.

In addition, if the sum of (a) the consideration per CCBC Share paid to shareholders of CCBC upon completion of the Proposal and (b) the amount per CCBC Share of all distributions declared after the Completion Date and prior to the completion of the Proposal (the sum of (a) and (b), the "Final Proposal Price") is higher than the US$6.40 Base Acquisition Price per CCBC Share, then the Purchaser shall pay to the Company an additional payment (the "Additional Consideration", and together with the Share Consideration and the Note Consideration, the "Aggregate Consideration") computed as follows:

The difference between the Final Proposal Price and the US$6.40 Base Acquisition Price
multiplied by
16,123,035 (being the aggregate number of Sale Shares and Conversion Shares)

The final Share Consideration and the final Note Consideration payable under the Agreement are dependent on whether CCBC declares any distribution between the date of the Agreement and the Completion Date, which is unknown as at the Latest Practicable Date. In addition to the foregoing, the final Aggregate Consideration is also dependent on whether Additional Consideration is payable which is dependent on the Final Proposal Price which is also unknown as at the Latest Practicable Date.

As disclosed in the Purchaser's announcement dated 8 May 2015 released on the HKExnews website (the "Purchaser's Announcement"), the Company understands that the Purchaser has also entered into a conditional purchase agreement dated 8 May 2015 with Magnum Opus International Holdings Limited, a company incorporated in the British Virgin Islands ("Magnum"), pursuant to which Magnum has agreed to sell and the Purchaser has agreed to purchase from Magnum the Magnum Note[2]

[1] On 25 August 2014, the Company entered into a conditional convertible note sale agreement (the "**Acquisition Agreement**") pursuant to which the Company acquired the Convertible Note from the Purchaser. The Company completed the acquisition of the Convertible Note on 10 November 2014. Under the terms of the Acquisition Agreement, the Purchaser is entitled to the interest payable on the Convertible Note up to and including 10 November 2014. Therefore, notwithstanding that the Note Consideration payable by the Purchaser to the Company under the terms of the Agreement includes the total amount of interest accrued but unpaid on the Convertible Note during the period from 3 October 2014 to the Completion Date, the Company is required to pay over to the Purchaser, the interest accrued but unpaid on the Convertible Note for the period from 3 October 2014 to 10 November 2014 pursuant to the terms of Acquisition Agreement (the "**Purchaser's Entitlement**"). The Purchaser's Entitlement amounts to US$179,861.

[2] The Magnum Note constitutes 50% of the original convertible note of US$50,000,000 principal amount issued by CCBC to the Purchaser on 3 October 2012; the remainder 50% of which is the Convertible Note. For more information on the Company's acquisition of the Convertible Note, please refer to footnote 1 on page 9 of the Circular.

The Company and Magnum had entered into a facility agreement dated 25 August 2014 (details of which are set out in the Company's announcements dated 25 August 2014, 10 September 2014 and 17 October 2014) (the "Facility Agreement"). Pursuant to the terms of the Facility Agreement, Magnum shall ensure that the proceeds from its sale of the Magnum Note are first applied towards prepayment of the loan and any accrued interest under the Facility Agreement in full. Based on an assumed completion date for the Purchaser's acquisition of the Magnum Note of 16 November 2015, the amount outstanding under the Facility Agreement (including interest) will be approximately US$47,492,000.

9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

Not applicable as no forecast or prospect statement has been previously disclosed to shareholders.

10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months

A Focused Growth-Path through the use of Network Effects

The Group is riding on the growth of emerging Asian nations by expanding its geographical footprint for cord blood and umbilical cord lining banking business as well as other newly-introduced products catering to the mother and child segment. Initiatives under this strategy include the following:

- On 10 November 2014, the Group announced that it had completed the acquisition of a convertible note issued by CCBC for approximately US$44 million, which will result in its interest in CCBC rising to approximately 17.79% of the enlarged share capital of CCBC, assuming full conversion of the note.

- On 3 March 2014, the Group announced that it has extended its strategic alliance and co-operation with CordLabs Asia Pte. Ltd. ("CAP") and NYSE-listed China Cord Blood Corporation (“CCBC”), in relation to the provision of human postnatal umbilical cord tissue storage services to certain territories in the People's Republic of China (the "PRC").

- On 9 December 2013, the Group announced that it has acquired a further 11.89% interest (“Additional Acquisition”) in StemLife, an associated company of the Company listed on the ACE Market of the Bursa Malaysia, for a cash payment of approximately RM17.66 million. Following the Additional Acquisition, the Company holds approximately 31.81% of the issued and paid-up share capital in StemLife. The consideration for the Additional Acquisition was satisfied by the Group fully in cash funded through a combination of borrowings and IPO proceeds. Prior to this, the Group announced on 4 October 2013 that it had completed the acquisition of an initial 19.92% interest in StemLife.

The Group is also looking to provide other adjacent products and services that cater to the mother and child segment, in addition to cord blood and umbilical cord lining banking services. Initiatives under this strategy include:

- On 30 April 2014, the Group announced that the Company had entered into a licensing agreement with StemLife; to jointly explore and develop umbilical cord tissue related new services based on cellular technology in Malaysia.
- In April 2014, Metascreen™ was launched in both the Philippines and Hong Kong.
- The Group is expected to launch adjacent products and services into all the markets this year, and in some cases, leveraging on the power of product and service bundling.

Cordlife also announced on 8 May 2015 that the Group has entered into a conditional purchase agreement with Golden Meditech Holdings Limited, pursuant to which Cordlife has agreed to sell and Golden Meditech has agreed to purchase from Cordlife 7,314,015 ordinary shares in CCBC and a 7% senior unsecured convertible note due 3 October 2017 issued by CCBC to Cordlife in the principal amount of US$25 million (the "Proposed Disposal"). The Proposed Disposal allows Cordlife to realise value in its investment in CCBC at a net gain of approximately S$46,184,000[3]. The proceeds from Proposed Disposal may be used for the Group's future business expansion, or be used to deleverage the financial position of the Group and/or for distribution to shareholders of the Group. The completion of the Proposed Disposal is conditional upon the fulfilment of the salient terms of the purchase agreement as per the SGX announcement dated 8 May 2015. On 26 August 2015, the Group announced that it will convene an Extraordinary General Meeting on to 14 September 2015 to seek Shareholders' approval.

Moving forward, the Group remains committed to developing its market leadership in cord blood and umbilical cord lining banking in Asia while continuing with its plans to introduce new consumer healthcare products catering to the mother and child. Barring any unforeseen circumstances and excluding fair value changes on financial asset designated at fair value through profit and loss, fair value changes on derivative, non-operating exchange differences, share of results of associate, impairment loss on investment in associate and any other one-off items, the Group expects its core business to remain profitable for FY2016.

[3] This figure does not include the Additional Consideration which is dependent on the Final Proposed Price as explained in the Company's announcement on 8 May 2015. For more information, please refer to the announcement on the Proposed Disposal of shares in China Cord Blood Corporation and 7% senior unsecured convertible note due 2017.

11. Dividends

(a) ***Current financial period reported on***

Any dividend recommended for the current financial period reported on?

The Board has proposed the following dividend subject to the approval of the shareholders at the forthcoming annual general meeting for FY2015 ("AGM").

Name of Dividend	Final
Dividend Type	Tax exempt (1-tier) dividend
Dividend Amount	S$0.010 per ordinary share
Tax Rate	Exempt (1-tier)

(b) ***Corresponding period of the immediately preceding financial year***

Any dividend declared for the corresponding period of the immediately preceding financial year? Yes

Name of Dividend	Final
Dividend Type	Tax exempt (1-tier) dividend
Dividend Amount	S$0.010 per ordinary share
Tax Rate	Exempt (1-tier)

(c) ***The date the dividend is payable.***

The final dividend will be paid on 6 November 2015, subject to the approval of the shareholders at the forthcoming Annual General Meeting.

(d) ***Book closure date.***

Notice is hereby given that, subject to the approval of the shareholders at the forthcoming Annual General Meeting, the Register of Members and the Transfer Books of the Company will be closed on 26 October 2015 ("Book Closure Date") for the purpose of determining members' entitlement to the final dividend ("Dividend").

Duly completed registrable transfers received by the Company's Share Registrar Tricor Barbinder Share Registration Services at 80 Robinson Road, #02-00 Singapore 068898 up to 5.00pm on 23 October 2015 ("Entitlement Date") will be registered to determine members' entitlements to the Dividend. Subject as aforesaid, persons whose securities accounts with The Central Depository (Pte) Limited are credited with ordinary shares in the capital of the Company as at 5.00pm on the Entitlement Date will be entitled to the Dividend.

12. If no dividend has been declared/recommended, a statement to that effect

Not applicable

13. Interested person transactions

The Company has not obtained a general mandate from shareholders for interested person transactions.

There were no interested party transactions of $100,000 or more for the financial year reported on.

14. Disclosure on the use of IPO proceeds

The breakdown of the use of proceeds by the Group for working capital and general corporate purposes is as follows:

	Amount (S$ million)
Amount utilised as working capital and general corporate purposes:	
Salaries, central provident fund contributions and other short-term benefits	1.20
Trade purchases	1.10
Legal and professional fees	0.55
Advertising and marketing expenses	0.90
Administrative expenses	0.70
Business travel expenses	0.20
Income tax and GST	0.20
Establishment of S$500 million Multicurrency Debt Issuance Programme	0.03
Issue of S$120 million 4.9% Fixed Rate Notes due 2017	1.20
Magnum Loan	0.09
CGL Acquisition	0.23
Total	**6.40**

As at 30 June 2015, the Group has utilised approximately S$28.1 million of the IPO Proceeds as follows:

Intended Use of IPO Proceeds	Estimated amount S$ (in millions)	Estimated percentage of gross proceeds raised from the IPO	Amount utilised S$ (in millions)	Percentage of gross proceeds raised from the IPO
Development and expansion of business and operations in Singapore and overseas	16.6	55.9%	16.6	55.9%
Renovation of new headquarters and facility at Yishun, A'Posh Bizhub	3.0	10.1%	1.0	3.4%
Investments in infrastructure relating to information technology	2.0	6.7%	0.4	1.3%
Working capital and general corporate purposes	4.7	15.8%	6.4	21.5%
Expenses incurred in connection with the IPO	3.4	11.5%	3.7	12.5%
	29.7	100.0%	28.1	94.6%

Note:

(1) The numbers in the table above may not exactly add due to rounding.

The Group made an announcement on 30 April 2013, on the Use of Proceeds from Initial Public Offering ("IPO") that the Company had substantially completed renovation of new headquarters and facility at Yishun, A'Posh Bizhub and the actual expenses incurred in connection with the renovation works were approximately S$1.0 million. The balance of approximately S$2.0 million from the S$3.0 million which was originally allocated for the renovation works was re-deployed for working capital and general corporate purposes.

The above utilisation of the Company's IPO Proceeds is in accordance with the intended use stated and percentage allocated in the disclosure on page 25 of the Company's prospectus dated 21 March 2012 and the announcement on Use of Proceeds from Initial Public Offering ("IPO") dated 30 April 2013.

The Company will make further announcements via SGXNET as and when the balance of the IPO Proceeds are materially disbursed in accordance with Rule 704(30) of the Listing Manual of the SGX-ST.

15. Disclosure on the use of placement proceeds

Capitalised terms used herein, unless otherwise defined, have the meanings as defined in the announcements on Private Placement Of An Aggregate Of Up To 26,838,000 New Ordinary Shares In The Capital Of The Company dated 2 October 2013, 11 October 2013 and 14 October 2013.

The Company issued 26,838,000 Placement Shares at issue price of S$1.25 by way of private placement (the “Private Placement”) to raise aggregate gross proceeds of S$33,547,500 on 14 October 2013.

The Board of Directors (the “Board”) of the Company wishes to announce that the Group have utilised approximately S$8.3 million out of the approximately S$33.5 million raised from the Private Placement.

The Group utilised a further approximately S$2.9 million in connection with furthering and supporting its operations in its enlarged geographical footprint and funding strategic investments and an additional approximately S$0.7 million for general working capital purposes.

The breakdown of the total use of proceeds by the Group for general working capital purposes is as follows:

	Amount (S$ million)
Amount utilised as working capital:	
Trade purchases	2.2
Legal and professional fees	0.1
Total	**2.3**

As at 30 June 2015, the Group has utilised approximately S$8.3 million of the Private Placement proceeds as follows:

Intended Use of Placement Proceeds	Estimated amount (S$ m)	Estimated percentage of gross proceeds raised from the Private Placement	Amount utilised (S$ m)	Percentage of gross proceeds raised from the Private Placement
Further, fund and support the Group's operations in connection with its enlarged geographical footprint developed after the Company's initial public offering, including funding of additional strategic investments, joint ventures, acquisitions and/or strategic alliances as and when opportunities materialise and are deemed appropriate by the Board	23.5	70.1%	5.4	16.1%
General working capital	8.6	25.7%	2.3	6.9%
Expenses incurred in connection with the Private Placement	1.4	4.2%	0.6	1.8%
	33.5	100.0%	8.3	24.8%

Note:

The numbers in the table above may not exactly add due to rounding.

The Board is of the view that the above utilisation is in accordance with the intended use disclosed in the announcement dated 2 October 2013.

The Board is also pleased to announce that due to the Company's prudent management of financial resources and negotiations with vendors, there is a balance of approximately S$0.8 million from the approximately S$1.4 million which was originally allocated to pay for expenses incurred in connection with the Private Placement. The Board, after deliberation, deemed it in the best interest of the Company and its shareholders to re-deploy the said balance amount for general working capital purposes.

The Company will make further announcements via SGXNET as and when the balance of the Private placement Proceeds are materially disbursed in accordance with Rule 704(30) of the Listing Manual of the SGX-ST.

16. Segmented revenue and results for business or geographical segments (of the group) in the form presented in the issuer's most recently audited annual financial statements, with comparative information for the immediately preceding year

Segment revenue

	Banking S$'000	**Diagnostics** S$'000	**Others*** S$'000	**Total** S$'000
Year ended 30 June 2015				
Revenue from external customers	57,436	103	44	57,583
Total consolidated revenue				57,583
Year ended 30 June 2014				
Revenue from external customers	48,951	7	129	49,087
Total consolidated revenue				49,087

Segment results

	Banking S$'000	**Diagnostics** S$'000	**Others*** S$'000	**Total** S$'000
Year ended 30 June 2015				
Depreciation and amortisation	(1,653)	(35)	–	(1,688)
Share of results of associates	(436)	–	–	(436)
Segment profit/(loss)	5,650	(248)	(2)	5,400
Impairment loss on investment in associate				(2,646)
Fair value gain on investment properties				265
Fair value changes on financial asset designated at fair value through profit or loss				10,364
Fair value changes on derivative				12,922
Exchange differences				4,653
Finance income				7,043
Finance costs				(4,597)
Profit before income tax				33,404
Income tax				(1,279)
Profit for the year				32,125

	Banking	Diagnostics	Others*	Total
	S$'000	S$'000	S$'000	S$'000
Year ended 30 June 2014				
Depreciation and amortisation	(1,508)	–	–	(1,508)
Share of results of associates	(2,350)	–	–	(2,350)
Segment profit/(loss)	6,470	(10)	(17)	6,443
Fair value gain on investment properties				110
Fair value changes on financial asset designated at fair value through profit or loss				18,716
Gain on transfer from associate to financial asset designated at fair value through profit or loss				6,297
Finance income				288
Profit before income tax				31,854
Income tax				(1,474)
Profit for the year				30,380

* Others refers to results of subsidiaries which principal activities are not that of the provision of cord blood and umbilical cord lining banking and diagnostics services.

17. In the review of performance, the factors leading to any material changes in contributions to turnover and earnings by the business or geographical segments

Please refer to paragraph 8.

18. A breakdown of sales as follows:

		Group		
		FY2015	FY2014	+/(-) Increase/ (Decrease)
		S$'000	S$'000	%
(a)	Revenue reported for first half year	27,519	23,468	17.3
(b)	(Loss)/profit after tax before deducting minority interests reported for the first half year	(6,890)	12,903	n.m.
(c)	Revenue reported for second half year	30,064	25,619	17.4
(d)	Profit after tax before deducting minority interests reported for the second half year	39,015	17,477	>100.0

19. A breakdown of the total annual dividend (in dollar value) for the issuer's latest full year and its previous full year as follows:

	Full year 2015	Full year 2014
	S$	S$
Interim dividend	2,592,974	2,673,254
Final dividend	2,592,974	2,664,503
Total	5,185,948	5,337,757

19. Persons occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director, chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(13). If there are no such persons, the issuer must make the appropriate negative statement

The Company confirms that none of the persons occupying managerial positions in the Company or any of its principal subsidiaries is a relative of a director or chief executive officer or substantial shareholder of the Company.

By Order of the Board

Yee Pinh Jeremy
Executive Director and Chief Executive Officer
27 August 2015